309 related articles for article (PubMed ID: 27004444)
1. Clinical Impact of Heparin Kinetics During Catheter Ablation of Atrial Fibrillation: Meta-Analysis and Meta-Regression.
Briceno DF; Villablanca PA; Lupercio F; Kargoli F; Jagannath A; Londono A; Patel J; Otusanya O; Brevik J; Maraboto C; Berardi C; Krumerman A; Palma E; Kim SG; Natale A; DI Biase L
J Cardiovasc Electrophysiol; 2016 Jun; 27(6):683-93. PubMed ID: 27004444
[TBL] [Abstract][Full Text] [Related]
2. Management of Intraprocedural Anticoagulation in Patients on Non-Vitamin K Antagonist Oral Anticoagulants Undergoing Catheter Ablation for Atrial Fibrillation: Understanding the Gaps in Evidence.
Martin AC; Godier A; Narayanan K; Smadja DM; Marijon E
Circulation; 2018 Aug; 138(6):627-633. PubMed ID: 30354610
[TBL] [Abstract][Full Text] [Related]
3. Appropriate intraprocedural initial heparin dosing in patients undergoing catheter ablation for atrial fibrillation receiving uninterrupted non-vitamin-K antagonist oral anticoagulant treatment.
Zhang RF; Ma CM; Wang N; Yang MH; Li WW; Yin XM; Dong YX; Yu XH; Xiao XJ; Xia YL; Gao LJ
BMC Cardiovasc Disord; 2021 Apr; 21(1):214. PubMed ID: 33906609
[TBL] [Abstract][Full Text] [Related]
4. Catheter ablation of left atrial arrhythmias on uninterrupted oral anticoagulation with vitamin K antagonists: What is the relationship between international normalized ratio, activated clotting time, and procedure-related complications?
Kottmaier M; Bourier F; Semmler V; Telishevska M; Koch-Büttner K; Lennerz C; Lengauer S; Kornmayer M; Rousseva E; Brooks S; Brkic A; Grebmer C; Kolb C; Hessling G; Deisenhofer I; Reents T
J Cardiovasc Electrophysiol; 2017 Dec; 28(12):1415-1422. PubMed ID: 28800176
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of nonvitamin K antagonist oral anticoagulants during catheter ablation of atrial fibrillation: A systematic review and meta-analysis.
Ge Z; Faggioni M; Baber U; Sartori S; Sorrentino S; Farhan S; Chandrasekhar J; Vogel B; Qadeer A; Halperin J; Reddy V; Dukkipati S; Dangas G; Mehran R
Cardiovasc Ther; 2018 Oct; 36(5):e12457. PubMed ID: 29971964
[TBL] [Abstract][Full Text] [Related]
6. Influence of periprocedural anticoagulation strategies on complication rate and hospital stay in patients undergoing catheter ablation for persistent atrial fibrillation.
Gunawardene M; Willems S; Schäffer B; Moser J; Akbulak RÖ; Jularic M; Eickholt C; Nührich J; Meyer C; Kuklik P; Sehner S; Czerner V; Hoffmann BA
Clin Res Cardiol; 2017 Jan; 106(1):38-48. PubMed ID: 27435077
[TBL] [Abstract][Full Text] [Related]
7. Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants.
Brinkmeier-Theofanopoulou M; Tzamalis P; Wehrkamp-Richter S; Radzewitz A; Merkel M; Schymik G; van Mark G; Bramlage P; Schmitt C; Luik A
BMC Cardiovasc Disord; 2018 Apr; 18(1):71. PubMed ID: 29703158
[TBL] [Abstract][Full Text] [Related]
8. Short-Term Heparin Kinetics during Catheter Ablation of Atrial Fibrillation.
Gabus V; Rollin A; Maury P; Forclaz A; Pascale P; Dhutia H; Bisch L; Pruvot E
Pacing Clin Electrophysiol; 2015 Oct; 38(10):1142-50. PubMed ID: 26014444
[TBL] [Abstract][Full Text] [Related]
9. Continuous and minimally-interrupted direct oral anticoagulant are both safe compared with vitamin K antagonist for atrial fibrillation ablation: An updated meta-analysis.
Ha FJ; Barra S; Brown AJ; Begley DA; Grace AA; Agarwal S
Int J Cardiol; 2018 Jul; 262():51-56. PubMed ID: 29606512
[TBL] [Abstract][Full Text] [Related]
10. An updated meta-analysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupted anticoagulation in atrial fibrillation catheter ablation.
Cardoso R; Knijnik L; Bhonsale A; Miller J; Nasi G; Rivera M; Blumer V; Calkins H
Heart Rhythm; 2018 Jan; 15(1):107-115. PubMed ID: 28917562
[TBL] [Abstract][Full Text] [Related]
11. Differences in activated clotting time among uninterrupted anticoagulants during the periprocedural period of atrial fibrillation ablation.
Nagao T; Inden Y; Yanagisawa S; Kato H; Ishikawa S; Okumura S; Mizutani Y; Ito T; Yamamoto T; Yoshida N; Hirai M; Murohara T
Heart Rhythm; 2015 Sep; 12(9):1972-8. PubMed ID: 25881495
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of safety and efficacy of oral anticoagulants in patients requiring catheter ablation for atrial fibrillation.
Rahman H; Khan SU; DePersis M; Hammad T; Nasir F; Kaluski E
Cardiovasc Revasc Med; 2019 Feb; 20(2):147-152. PubMed ID: 29786530
[TBL] [Abstract][Full Text] [Related]
13. Lower Major Bleeding Rates with Direct Oral Anticoagulants in Catheter Ablation of Atrial Fibrillation: an Updated Meta-analysis of Randomized Controlled Studies.
Brunetti ND; Tricarico L; Tilz RR; Heeger CH; De Gennaro L; Correale M; Ieva R; Di Biase M; Rillig A; Metzner A; Santoro F
Cardiovasc Drugs Ther; 2020 Apr; 34(2):209-214. PubMed ID: 32080786
[TBL] [Abstract][Full Text] [Related]
14. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation.
Di Biase L; Callans D; Hæusler KG; Hindricks G; Al-Khalidi H; Mont L; Cosedis Nielsen J; Piccini JP; Schotten U; Kirchhof P
Europace; 2017 Jan; 19(1):132-138. PubMed ID: 28130378
[TBL] [Abstract][Full Text] [Related]
15. Periprocedural management of anticoagulation for atrial fibrillation catheter ablation in direct oral anticoagulant-treated patients.
Martin AC; Lessire S; Leblanc I; Dincq AS; Philip I; Gouin-Thibault I; Godier A
Clin Cardiol; 2018 May; 41(5):646-651. PubMed ID: 29532536
[TBL] [Abstract][Full Text] [Related]
16. Uninterrupted New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Ablation of Atrial Fibrillation: A Meta-analysis.
Nairooz R; Ayoub K; Sardar P; Payne J; Almomani A; Pothineni NV; Shailesh F; Aronow WS; Mukherjee D
Can J Cardiol; 2016 Jun; 32(6):814-23. PubMed ID: 26810476
[TBL] [Abstract][Full Text] [Related]
17. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
[TBL] [Abstract][Full Text] [Related]
18. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis.
Caldeira D; Rodrigues FB; Barra M; Santos AT; de Abreu D; Gonçalves N; Pinto FJ; Ferreira JJ; Costa J
Heart; 2015 Aug; 101(15):1204-11. PubMed ID: 26037103
[TBL] [Abstract][Full Text] [Related]
19. Effect of therapeutic INR on activated clotting times, heparin dosage, and bleeding risk during ablation of atrial fibrillation.
Gautam S; John RM; Stevenson WG; Jain R; Epstein LM; Tedrow U; Koplan BA; McClennen S; Michaud GF
J Cardiovasc Electrophysiol; 2011 Mar; 22(3):248-54. PubMed ID: 20812929
[TBL] [Abstract][Full Text] [Related]
20. Influence of the concomitant use of heparin on the effects of warfarin during catheter ablation for atrial fibrillation.
Inada K; Matsuo S; Tokutake K; Yokoyama K; Hioki M; Narui R; Ito K; Tanigawa S; Yamashita S; Tokuda M; Shibayama K; Miyanaga S; Sugimoto K; Yoshimura M; Yamane T
Heart Vessels; 2016 Mar; 31(3):397-401. PubMed ID: 25471944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
